Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT00102479 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Aripiprazole Pharmacokinetics (PK) and Tolerability Study in Children and Adolescents

StatusCompleted
PhasePhase 1
Started
View on ClinicalTrials.gov ↗

Record History

  1. Phase: Phase 2 to Phase 1 Results first posted: Jun 22, 2026 · Enrollment target: 21 · Primary completion date: Jul 1, 2005 · 4 morev5 Show all 8 changesShow less
    • Results first posted: Jun 22, 2026
    • Enrollment target: 21
    • Primary completion date: Jul 1, 2005
    • Completion date: Jul 2005 to Jul 1, 2005
    • Start date: Jul 2004 to Jul 1, 2004
    • Eligibility criteria expanded, about 399 words
    • Study arms: 0 to 3

    See this version in full on ClinicalTrials.gov ↗

  2. Study Status, Contacts/Locationsv4
  3. Re-verified, no change to tracked fieldsv3
  4. Trial status: Recruiting to Completed Site details revised at 3 of 3 sitesv2 Show all 2 changesShow less
    • Site details revised at 3 of 3 sites
  5. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
The purpose of this trial is to assess the safety, tolerability and pharmacokinetics of aripiprazole tablets following oral administration to children and adolescents.
Trial Details
NCT Number NCT00102479
Lead Sponsor Otsuka Pharmaceutical Development & Commercialization, Inc.
Conditions Schizophrenia, Mania
Enrollment 21 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov